No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma

BACKGROUND: Sorafenib is a standard therapy for patients with advanced hepatocellular carcinoma (HCC). However, no predictive biomarkers of sorafenib efficacy have been discovered. Herein, we investigated the impact of body composition, such as skeletal muscle and visceral fat, on the prognosis of a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Liver Cancer
Autores principales: Saeki, Issei, Yamasaki, Takahiro, Maeda, Masaki, Kawano, Reo, Hisanaga, Takuro, Iwamoto, Takuya, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Formato: Artigo
Lenguaje:Inglês
Publicado: S. Karger AG 2018
Materias:
Original Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6249591/
https://ncbi.nlm.nih.gov/pubmed/30488024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000487858
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares